Bcwm LLC Acquires Shares of 110,279 Bristol-Myers Squibb (NYSE:BMY)

Bcwm LLC bought a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,279 shares of the biopharmaceutical company's stock, valued at approximately $6,237,000. Bristol-Myers Squibb comprises about 2.2% of Bcwm LLC's investment portfolio, making the stock its 20th biggest holding.

A number of other hedge funds have also made changes to their positions in the company. Fairway Wealth LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Dunhill Financial LLC lifted its stake in shares of Bristol-Myers Squibb by 39.8% during the third quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 189 shares during the period. Comprehensive Financial Planning Inc. PA acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth about $34,000. Westend Capital Management LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $38,000. Finally, Tacita Capital Inc acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Bank of America restated a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Citigroup upped their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Cantor Fitzgerald boosted their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Finally, Truist Financial lifted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $57.86.

Remove Ads

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Down 1.0 %

NYSE:BMY traded down $0.57 during trading hours on Thursday, reaching $59.03. 5,357,091 shares of the stock were exchanged, compared to its average volume of 12,708,499. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The stock has a market cap of $120.11 billion, a PE ratio of -13.36, a PEG ratio of 2.07 and a beta of 0.43. The firm has a 50 day moving average of $58.74 and a 200 day moving average of $56.54.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, equities analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 4.20%. Bristol-Myers Squibb's dividend payout ratio is -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.